The Zebrafish: A powerful platform for in vivo, HTS drug discovery

Assay and Drug Development Technologies

Volumn 9, Issue 4, 2011, Pages 354-361

  Delvecchio, Chris ^a   Tiefenbach, Jens ^a   Krause, Henry M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRAZ; ANGIOGENESIS INHIBITOR; BONE MORPHOGENETIC PROTEIN; CELL NUCLEUS RECEPTOR; CEREBLON PROTEIN; CLONIDINE; DORSOMORPHIN; GLYCOGEN SYNTHASE KINASE 3BETA; GREEN FLUORESCENT PROTEIN; GUANABENZ; GUANFACINE; HYBRID PROTEIN; LIOTHYRONINE; PRODRUG; PROTEIN; PROTEIN INHIBITOR; RED FLUORESCENT PROTEIN; TAU PROTEIN; THALIDOMIDE; THYROID HORMONE RECEPTOR; THYROXINE; TIRATRICOL; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

BEHAVIOR CHANGE; BIOLOGICAL MODEL; COST; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EMBRYO DEVELOPMENT; FLUORESCENCE; GENETIC DISORDER; GENETIC MODEL; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MORPHOLOGY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; TOXICITY TESTING; ZEBRA FISH;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; MOLECULAR TARGETED THERAPY; ZEBRAFISH;

EID: 84860389672     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0346     Document Type: Review

References (77)

1. Paul SM, Mytelka DS, Dunwiddie CT, et al.: How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9: 203-214.
2. Keseru GM, Makara GM: The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-212.
3. Macarron R: Critical review of the role of HTS in drug discovery. Drug Discov Today 2006;11:277-279.
4. Kari G, Rodeck U, Dicker AP: Zebrafish: An emerging model system for human disease and drug discovery. Clin Pharmacol Ther 2007;82:70-80.
5. Holder N, Xu Q: The zebrafish: An overview of its early development. Methods Mol Biol 2008;461:483-491.
6. Golling G, Amsterdam A, Sun Z, et al.: Insertional mutagenesis in zebrafish rapidly identifies genes essential for early vertebrate development. Nat Genet 2002;31:135-140.
7. Amatruda JF, Shepard JL, Stern HM, Zon LI: Zebrafish as a cancer model system. Cancer Cell 2002;1:229-231.
8. Stern HM, Zon LI: Cancer genetics and drug discovery in the zebrafish. Nat Rev Cancer 2003;3:533-539.
9. Drummond IA: Kidney development and disease in the zebrafish. J Am Soc Nephrol 2005;16:299-304.
10. Milan DJ, Macrae CA: Zebrafish genetic models for arrhythmia. Prog Biophys Mol Biol 2008;98:301-308.
11. Hughes I, Thalmann I, Thalmann R, Ornitz DM: Mixing model systems: Using zebrafish and mouse inner ear mutants and other organ systems to unravel the mystery of otoconial development. Brain Res 2006;1091:58-74.
12. Amatruda JF, Zon LI: Dissecting hematopoiesis and disease using the zebrafish. Dev Biol 1999;216:1-15.
13. Ingham PW: The power of the zebrafish for disease analysis. Hum Mol Genet 2009;18:R107-R112.
14. Paquet D, Bhat R, Sydow A, et al.: A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest 2009;119: 1382-1395.
15. Paquet D, Schmid B, Haass C: Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo. Neurodegener Dis 2010;7:99-102.
16. Chang S, Bray SM, Li Z, et al.: Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008;4:256-263.
17. Petrascheck M, Ye X, Buck LB: A high-throughput screen for chemicals that increase the lifespan of Caenorhabditis elegans. Ann N Y Acad Sci 2009;1170: 698-701.
18. Giacomotto J, Segalat L: High-throughput screening and small animal models, where are we? Br J Pharmacol 2010;160:204-216.
19. Zon LI, Peterson RT: In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005;4:35-44.
20. Fishman MC: Zebrafish genetics: The enigma of arrival. Proc Natl Acad Sci USA 1999;96:10554-10556.
21. Pichler FB, Laurenson S, Williams LC, Dodd A, Copp BR, Love DR: Chemical discovery and global gene expression analysis in zebrafish. Nat Biotechnol 2003;21:879-883.
22. Shin JT, Fishman MC: From Zebrafish to human: Modular medical models. Annu Rev Genomics Hum Genet 2002;3:311-340.
23. Warren KS, Fishman MC: "Physiological genomics": Mutant screens in zebrafish. Am J Physiol 1998;275(1 Pt 2):H1-H7.
24. Liu TX, Zhou Y, Kanki JP, et al.: Evolutionary conservation of zebrafish linkage group 14 with frequently deleted regions of human chromosome 5 in myeloid malignancies. Proc Natl Acad Sci USA 2002;99:6136-6141.
25. Barbazuk WB, Korf I, Kadavi C, et al.: The syntenic relationship of the zebrafish and human genomes. Genome Res 2000;10:1351-1358.
26. Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC: A primer for morpholino use in zebrafish. Zebrafish 2009;6:69-77.
27. Kawakami K: Transposon tools and methods in zebrafish. Dev Dyn 2005;234: 244-254.
28. Moens CB, Donn TM, Wolf-Saxon ER, Ma TP: Reverse genetics in zebrafish by TILLING. Brief Funct Genomic Proteomic 2008;7:454-459.
29. Amacher SL: Emerging gene knockout technology in zebrafish: zinc-finger nucleases. Brief Funct Genomic Proteomic 2008;7:460-464.
30. Wheeler GN, Brandli AW: Simple vertebrate models for chemical genetics and drug discovery screens: Lessons from zebrafish and Xenopus. Dev Dyn 2009; 238:1287-1308.
31. Emelyanov A, Parinov S: Mifepristone-inducible LexPR system to drive and control gene expression in transgenic zebrafish. Dev Biol 2008;320:113-121.
32. Mathew LK, Sengupta S, Kawakami A, et al.: Unraveling tissue regeneration pathways using chemical genetics. J Biol Chem 2007;282:35202-35210.
33. Tong SK, Mouriec K, Kuo MW, et al.: A cyp19a1b-gfp (aromatase B) transgenic zebrafish line that expresses GFP in radial glial cells. Genesis 2009;47:67-73.
34. Thorpe JL, Doitsidou M, Ho SY, Raz E, Farber SA: Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation. Dev Cell 2004;6:295-302.
35. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA: Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003; 107:1355-1358.
36. Chan J, Bayliss PE, Wood JM, Roberts TM: Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell 2002;1:257-267.
37. Wang C, Tao W, Wang Y, et al.: Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 2010;58:418-426.
38. Hong CC: Large-scale small-molecule screen using zebrafish embryos. Methods Mol Biol 2009;486:43-55.
39. Murphey RD, Zon LI: Small molecule screening in the zebrafish. Methods 2006; 39:255-261.
40. Westerfield M: The zebrafish book a guide for the laboratory use of zebrafish Danio (Brachydanio) rerio. Text] http://zfin.org/zf-info/zfbook/zfbk. html. (Last accessed Dec 23, 2010).
41. White RM, Sessa A, Burke C, et al.: Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2008;2:183-189.
42. Makky K, Duvnjak P, Pramanik K, Ramchandran R, Mayer AN: A whole-animal microplate assay for metabolic rate using zebrafish. J Biomol Screen 2008;13: 960-967.
43. Tran TC, Sneed B, Haider J, et al.: Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 2007;67: 11386-11392.
44. Eimon PM, Rubinstein AL: The use of in vivo zebrafish assays in drug toxicity screening. Expert Opin Drug Metab Toxicol 2009;5:393-401.
45. Hill AJ, Teraoka H, Heideman W, Peterson RE: Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol Sci 2005;86:6-19.
46. Scholz S, Fischer S, Gundel U, Kuster E, Luckenbach T, Voelker D: The zebrafish embryo model in environmental risk assessment-applications beyond acute toxicity testing. Environ Sci Pollut Res Int 2008;15:394-404.
47. Liebler DC, Guengerich FP: Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005;4:410-420.
48. McGrath P, Li CQ: Zebrafish: A predictive model for assessing drug-induced toxicity. Drug Discov Today 2008;13:394-401.
49. Rubinstein AL: Zebrafish assays for drug toxicity screening. Expert Opin Drug Metab Toxicol 2006;2:231-240.
50. Hallare AV, Kohler HR, Triebskorn R: Developmental toxicity and stress protein responses in zebrafish embryos after exposure to diclofenac and its solvent, DMSO. Chemosphere 2004;56:659-666.
51. Fushimi S, Wada N, Nohno T, et al.: 17beta-Estradiol inhibits chondrogenesis in the skull development of zebrafish embryos. Aquat Toxicol 2009;95:292-298.
52. Liu YW, Chan WK: Thyroid hormones are important for embryonic to larval transitory phase in zebrafish. Differentiation 2002;70:36-45.
53. Bradfield JY, West JR, Maier SE: Uptake and elimination of ethanol by young zebrafish embryos. Neurotoxicol Teratol 2006;28:629-633.
54. Gundel U, Benndorf D, von Bergen M, Altenburger R, Kuster E: Vitellogenin cleavage products as indicators for toxic stress in zebra fish embryos: A proteomic approach. Proteomics 2007;7:4541-4554.
55. Reimers MJ, Flockton AR, Tanguay RL: Ethanol- and acetaldehyde-mediated developmental toxicity in zebrafish. Neurotoxicol Teratol 2004;26:769-781.
56. Dong W, Teraoka H, Kondo S, Hiraga T: 2, 3, 7, 8-tetrachlorodibenzo-p- dioxin induces apoptosis in the dorsal midbrain of zebrafish embryos by activation of arylhydrocarbon receptor. Neurosci Lett 2001;303:169-172.
57. Jones HS, Panter GH, Hutchinson TH, Chipman JK: Oxidative and conjugative xenobiotic metabolism in zebrafish larvae in vivo. Zebrafish 2010;7:23-30.
58. Wiegand C, Pflugmacher S, Giese M, Frank H, Steinberg C: Uptake, toxicity, and effects on detoxication enzymes of atrazine and trifluoroacetate in embryos of zebrafish. Ecotoxicol Environ Saf 2000;45:122-131.
59. Berghmans S, Butler P, Goldsmith P, et al.: Zebrafish based assays for the assessment of cardiac, visual and gut function-potential safety screens for early drug discovery. J Pharmacol Toxicol Methods 2008;58:59-68.
60. Ton C, Lin Y, Willett C: Zebrafish as a model for developmental neurotoxicity testing. Birth Defects Res A Clin Mol Teratol 2006;76:553-567.
61. Ito T, Ando H, Suzuki T, et al.: Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-1350.
62. Hao J, Ho JN, Lewis JA, et al.: In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 2010;5:245-253.
63. Yu PB, Hong CC, Sachidanandan C, et al.: Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008;4:33-41.
64. Kaufman CK, White RM, Zon L: Chemical genetic screening in the zebrafish embryo. Nat Protoc 2009;4:1422-1432.
65. Burns CG, Milan DJ, Grande EJ, Rottbauer W, MacRae CA, Fishman MC: Highthroughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat Chem Biol 2005;1:263-264.
66. Gehrig J, Reischl M, Kalmar E, et al.: Automated high-throughput mapping of promoter-enhancer interactions in zebrafish embryos. Nat Methods 2009;6: 911-916.
67. Vogt A, Cholewinski A, Shen X, et al.: Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn 2009;238:656-663.
68. Rihel J, Prober DA, Arvanites A, et al.: Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 2010;327:348-351.
69. Kokel D, Bryan J, Laggner C, et al.: Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol 2010;6:231-237.
70. Tiefenbach J, Moll PR, Nelson MR, et al.: A live zebrafish-based screening system for human nuclear receptor ligand and cofactor discovery. PLoS One 2010;5:e9797.
71. Gurnell M, Chatterjee VK: Nuclear receptors in disease: Thyroid receptor beta, peroxisome-proliferator-activated receptor gamma and orphan receptors. Essays Biochem 2004;40:169-189.
72. Nagy L, Schule R, Gronemeyer H: Twenty years of nuclear receptors: Conference on Nuclear Receptors: From Chromatin to Disease. EMBO Rep 2006;7:579-584.
73. Nilsson M, Dahlman-Wright K, Gustafsson JA: Nuclear receptors in disease: The oestrogen receptors. Essays Biochem 2004;40:157-167.
74. Swanson HI, Njar VC, Yu Z, et al.: Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos 2010;38: 539-544.
75. McIntosh BE, Hogenesch JB, Bradfield CA: Mammalian Per-Arnt-Sim proteins in environmental adaptation. Annu Rev Physiol 2010;72:625-645.
76. Ukai H, Ueda HR: Systems biology of mammalian circadian clocks. Annu Rev Physiol 2010;72:579-603.
77. Paulmurugan R, Massoud TF, Huang J, Gambhir SS: Molecular imaging of drugmodulated protein-protein interactions in living subjects. Cancer Res 2004; 64:2113-2119.